Rong Yin

Rongyin Biopharmaceutical is a Shanghai-based biotechnology company focused on the development of innovative circular RNA (circRNA) therapeutics. Founded in 2021 by Dr. Zefeng Wang, a leading expert in RNA biology, the company aims to address the limitations of traditional mRNA therapies, such as short half-life and high immunogenicity. Rongyin's proprietary platform specializes in the design, circularization, and delivery of RNA molecules that offer superior stability and prolonged protein expression. The company's current pipeline includes candidates for infectious disease vaccines, cancer immunotherapies, and protein replacement for rare diseases. By leveraging its deep expertise in RNA splicing and computational biology, Rongyin is positioned as a key player in the emerging circRNA landscape in China. The firm has successfully secured significant early-stage funding from prominent venture capital firms to advance its pre-clinical programs toward the clinic.